(Reuters) – German biopharmaceutical firm Immatics said on Thursday it plans to collaborate with British drugmaker GlaxoSmithKline (GSK) to develop immunotherapies targeting multiple cancer
Germany’s Immatics ties up with GSK to develop immunotherapies

Deere settles US right-to-repair lawsuit with $99 million fund, repair commitments
2h ago
Basketball-Shaq to launch professional dunk league
2h ago
Australia's most decorated soldier Ben Roberts-Smith arrested over alleged war crimes
1h ago
Exclusive-SpaceX lays out IPO details, targets early June roadshow, sources say
3h ago
Apple's foldable iPhone faces engineering snags, potential shipment delays, Nikkei Asia reports
1h ago
China targets Taiwan's chip prowess to evade global 'containment', Taipei government says
1h ago
